Diagnosis of Bone Metastases in Breast Cancer: Bone Scintigraphy, Fluoride-PET and FDG-PET
- Conditions
- Breast Cancer
- Registration Number
- NCT01224873
- Lead Sponsor
- Rigshospitalet, Denmark
- Brief Summary
Breast cancer can metastasize to the bones, which leads to another treatment if bone metastases are detected. The purpose of the study is to determine, if fluoride PET/CT is superior to bone scintigraphy with technetium. On the other side, the investigators would like to see if FDG-PET/CT is a reliable alternative to dedicated bone imaging to detect bone metastases in patients with breast cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 110
Inclusion Criteria
- histologically proven c. mammae
- clinically suspicion of bone metastases
Exclusion Criteria
- age under 18 years
- diabetes mellitus
- pregnancy
- other known malignant disease
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie 18F-NaF PET/CT's superior detection of bone metastases in breast cancer compared to 99mTc HDP scintigraphy?
How does FDG-PET/CT compare to bone scintigraphy in detecting skeletal metastases in estrogen receptor-positive breast cancer patients?
Which biomarkers correlate with improved diagnostic accuracy using fluoride PET/CT versus FDG-PET/CT in HER2-negative breast cancer metastases?
What adverse events are associated with 18F-NaF PET/CT versus 99mTc HDP bone scintigraphy in metastatic breast cancer imaging?
Are there emerging imaging agents or combination protocols outperforming NCT01224873's approaches for bone metastasis detection in breast cancer?
Trial Locations
- Locations (1)
Dep. of Nuclear Medicine & PET, Rigshospitalet
🇩🇰Copenhagen, Denmark